PSMA-PET/CT helps spot early prostate cancer recurrence
PET/CT imaging with gallium-68 prostate-specific membrane antigen (PSMA-11)...Read more on AuntMinnie.comRelated Reading: SNMMI: PET/CT with prostate agent changes therapy plans SNMMI: PET/CT may help guide prostate biopsies New PET tracer aids in metastatic prostate cancer PET tracer boosts detection of recurrent prostate cancer SNMMI: PET beats other modalities for prostate cancer
Publication date: Available online 21 September 2018Source: The Lancet HIVAuthor(s): Nancy A Hessol, Hannah Whittemore, Eric Vittinghoff, Ling C Hsu, Danning Ma, Susan Scheer, Sandra K SchwarczSummaryBackgroundCancer survivors are at increased risk for subsequent primary cancers. People living with HIV are at increased risk for AIDS-defining and non-AIDS-defining cancers, but little is known about their risk of first versus second primary cancers. We identified first and second primary cancers that occurred in above population expected numbers among people diagnosed with HIV in San Francisco, and compared first and second ...
Veterans who seek care for low-risk prostate cancer receive more imaging that...Read more on AuntMinnie.comRelated Reading: Can AI best quantitative MRI in prostate lesions? Multiparametric MRI aids in prostate cancer follow-up SNMMI: Early prostate cancer therapy extends lives SNMMI: Fluciclovine-PET changes prostate treatment MRI-based risk model improves prostate cancer detection
Reuters Health Information
Decision aids should ideally promote clinical equipoise. However, the data from this study suggest some variation to which this is applied, given the differing results on how they altered the pre-exposure intent to undergo or recommend PSA screening. Although there was some change of opinion, a common theme is that the pre-exposure intent was unchanged in the majority of individuals who worked through any of these decision aids. The results are somewhat similar to our experience with testing a decision aid in a randomized controlled trial of a controversial aspect of prostate cancer care.
With a new artificial intelligence (AI) algorithm, planning for radiation therapy...Read more on AuntMinnie.comRelated Reading: Can AI best quantitative MRI in prostate lesions? Breast cancer follow-up imaging varies widely SNMMI: Early prostate cancer therapy extends lives SNMMI: Fluciclovine-PET changes prostate treatment SNMMI: New therapy aids patients with neuroendocrine tumors
AbstractVenous thromboembolism (VTE) is a major public health issue; deep vein thrombosis (DVT) affects about 1/1000 patients. Each year, VTE kills more patients in Western Europe than breast cancer, prostate cancer, acquired immune deficiency syndrome (AIDS) and road traffic accidents combined and is responsible for the deaths of approximately 370,000 European citizens (Cohen et al. in Thromb Haemost 98:756 –764,2007; B ĕlohlávek et al. in Exp Clin Cardiol 18(2):129–138,2013). The recently published ATTRACT trial (Acute Venous Thrombosis Thrombus Removal with Adjunctive Catheter-directed Thrombolysis) ...
Multiparametric MRI is a valuable option for monitoring patients who have undergone...Read more on AuntMinnie.comRelated Reading: Faster MRI protocol avoids unneeded prostate biopsies Quantitative MRI could advance prostate cancer detection Fewer men opt for prostate cancer treatment False-positive screening results don't deter patients MRI-based risk model improves prostate cancer detection
Swedish and Dutch researchers are reporting early progress in combining nanoSPECT/CT...Read more on AuntMinnie.comRelated Reading: SNMMI: Early prostate cancer therapy extends lives SNMMI: New therapy aids patients with neuroendocrine tumors Novel PET tracer shows promise for neuroendocrine tumors PET tracer may aid diagnosis of inflammatory bowel disease New therapeutic agent could treat prostate cancer
There is exciting news in the area of clinical bacteriology. The FDA has approved the T2 Biosystems bacterial panel for the rapid detection of septicemia (see: T2 Biosystems Receives FDA Clearance to Market T2Bacteria Panel for Detection of Sepsis-Causing Pathogens), Below is an excerpt from the article:T2 Biosystems...announced that it has received market clearance from the U.S. Food and Drug Administration (FDA) for the T2 Bacteria Panel for the direct detection of bacterial species in human whole blood specimens from patients with suspected bloodstream infections. The T2Bacteria Panel... provides sensitive det...
Aim: Tissue diagnosis of prostate cancer is obtained from TRUS (Transrectal ultrasound) biopsy, which can misdiagnose up to a third of cases. Multiparametric Magnetic Resonance Imaging(MpMRI) aids localizing prostate abnormality prior to TRUS biopsy. Our local hospital's criteria for pre-TRUS MRI prostate are: Age